ResMed: ‘(We’re) well-positioned to capitalize on once-in-a-generation opportunities’
By HME News Staff
Updated 3:59 PM CST, Thu January 30, 2025
SAN DIEGO – ResMed reported second quarter 2025 revenue increased to $1.3 billion, a 10% increase on a constant currency basis year over year.
The company reported revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 12%.
Other financial results for the quarter:
- Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%
- Income from operations increased 52%; non-GAAP income from operations up 19%
- Operating cash flow was $309 million
- Diluted earnings per share were $2.34; non-GAAP diluted earnings per share were $2.43
“Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS growth were the result of increased demand for our sleep health and breathing health products and digital health solutions that people love, as well as our laser-focus on operational excellence,” said Chairman and CEO Mick Farrell. “We delivered 10% year-over-year revenue growth, 230 bps improvement in gross margin, and $309 million of operating cash flow. These results are a continuation of the incredible commitment from our team to create a clear market-leading value proposition in connected digital health. Our ecosystem is unmatched and ResMed is well-positioned to capitalize on the once-in-a-generation opportunities we have with the recent introduction and adoption of consumer wearables that track sleep health, as well as use of GLP-1 therapies. We believe these developments will drive increased patient flow as we continue to educate people on the benefits of healthy sleep and breathing, with care delivered right in their own home.”
Comments